SynthesisFrontiers in public health2026
Efficacy and safety of direct oral anticoagulants in pediatric patients: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thromboembolic events (TE) are increasingly recognized in pediatric patients, necessitating optimal antithrombotic therapy. While direct oral anticoagulants (DOACs) offer potential advantages over standard of care (SOC) such as heparin, comprehensive evidence regarding their use for treatment and prophylaxis remains limited. Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of these two classes of anticoagulants. Methods: We searched PubMed, Embase, Web of Science, and ClinicalTrials.gov up to November 27, 2025, for relevant randomized controlled trials (RCTs) comparing DOACs with SOC in pediatric patients. Data were synthesized using fixed- or random-effects models to calculate risk ratios (RRs) with 95% confidence intervals (CIs). Results: Eight RCTs involving 2,002 pediatric patients were included. In terms of efficacy, DOACs were associated with a significant reduction in TE recurrence in treatment studies ( Conclusion: DOACs represent an effective alternative to SOC for the treatment and prevention of thromboembolism in children, demonstrating superior efficacy without increasing the risk of bleeding events. Systematic review registration: PROSPERO https://www.crd.york.ac.uk/PROSPERO/view/CRD42024506541, CRD42024506541.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.